Epilepsy Research Stanford: A New Target for Seizures

Epilepsy is a brain condition where nerve cells sometimes fire in an uncontrolled burst, causing a seizure. For most people diagnosed, standard anti-seizure medications work reasonably well and keep episodes under control.

But not for everyone. Stanford's own child neurology division notes that nearly 30% of children with epilepsy don't respond adequately to conventional drug treatment. That's not a small subset, it's close to a third of pediatric cases, and it's exactly the group where new research matters most.

This category, often called drug-resistant or refractory epilepsy, is where a lot of current research effort is concentrated, including a notable 2026 finding out of Stanford Medicine that's reshaping how scientists think about why seizures sometimes get worse over time instead of staying stable.

The New Discovery: Myelination Gone Wrong

Here's the finding, and I'll try to unpack it without drowning you in jargon. The brain has a normal process called myelination, where a fatty coating called myelin wraps around nerve fibers to help electrical signals travel faster. It's a completely normal part of learning and brain development, not something inherently dangerous.

Dr. Juliet Knowles and colleagues at Stanford found that seizures themselves can hijack this normal process, a phenomenon they're calling maladaptive myelination. In other words, having a seizure can trigger changes in myelin around the very brain circuits involved in producing more seizures, which may help explain why epilepsy sometimes worsens progressively rather than staying at a stable severity.

That's a meaningfully different way of thinking about epilepsy progression. It's not just that misfiring neurons cause seizures, it's that seizures may be actively reshaping brain wiring in a way that makes future seizures more likely. If that holds up in further research, it opens up an entirely new category of potential treatment target, one aimed at that maladaptive myelination process itself rather than only dampening neuron activity the way most current drugs do.

In clinical practice, this is the distinction that's easy to lose in translation: finding a new mechanism isn't the same as having a new treatment ready to prescribe. This work is still at the level of understanding disease biology, not a therapy sitting in a pharmacy. It's genuinely exciting for the field, but it's years, not months, from anything a patient would encounter in clinic.

Beyond Medication: What's Already Available for Hard-to-Treat Cases

While that research develops, Stanford's epilepsy program, rated at the highest level by the National Association of Epilepsy Centers, continues offering established options for patients whose seizures don't respond to medication alone. These include epilepsy surgery to remove or disconnect the specific brain tissue generating seizures, and neuromodulation devices like responsive neurostimulation (RNS), deep brain stimulation (DBS), and vagus nerve stimulation (VNS), which work by delivering carefully timed electrical signals to interrupt seizure activity.

These aren't experimental anymore, they're established parts of comprehensive epilepsy care at specialized centers, though they're typically considered only after medication options have been thoroughly tried and haven't worked well enough.

There's also been progress on the diagnostic side worth mentioning. Newer under-the-skin electrode devices now allow for continuous, real-world seizure tracking outside a hospital's monitoring unit, which matters because seizures caught only during a short hospital stay don't always reflect a patient's actual pattern of episodes.

An Unexpected Finding: Blood Pressure Drugs and Epilepsy Risk

One other Stanford-linked finding worth mentioning, mostly because it's a good example of how epilepsy research sometimes turns up surprises from unrelated fields. An analysis of more than two million patient records found that people taking angiotensin receptor blockers, a common class of blood pressure medication, were less likely to develop epilepsy than those not taking them.

That's an observational association, not proof that the drug prevents epilepsy, and it shouldn't be read as a reason to start or change blood pressure medication for epilepsy prevention. It's the kind of early signal that usually prompts further, more targeted research rather than an immediate change in how doctors prescribe.

What This Means If You or Your Child Has Epilepsy

Should this research change anything about your current treatment plan? Not directly, not yet. Early mechanistic discoveries like the myelination finding are important for the field's long-term direction, but they don't translate into a new prescription or procedure today.

What it should do is reinforce something worth acting on now: if seizures aren't well controlled on your current medication, that's worth raising proactively with a neurologist, ideally one with epilepsy-specific experience, rather than assuming drug-resistant epilepsy simply has no further options. Surgical and device-based treatments exist precisely for this group, and referral to a comprehensive epilepsy center is a reasonable ask if standard treatment isn't cutting it.